Navigation Links
Ethicon Submits Biologic License Application to the FDA for the Fibrin Pad
Date:11/18/2010

SOMERVILLE, N.J., Nov. 18, 2010 /PRNewswire/ -- Ethicon, Inc., a worldwide leader in surgical care, announced today that the company has submitted a Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the Fibrin Pad, a novel product candidate that combines Ethicon's biomaterials and plasma-derived biologics (Human Fibrinogen and Human Thrombin), to aid in stopping soft tissue bleeding during surgery.

"Excessive bleeding during surgical procedures is a serious and challenging problem. Currently available treatment options in these settings are not always satisfactory and so surgeons are looking for a safe and effective alternative," said Dan Wildman, Worldwide President with responsibility for the Ethicon Biosurgery Business. "Our development of this product candidate is aimed at meeting this significant unmet need."

The Fibrin Pad is intended for use by surgeons as an adjunct to hemostasis when surgical methods are ineffective or impractical to control bleeding. Its novel design combines two methods of action (the mechanical mechanism of the device coupled with the biologic mechanism of the two biologics).

"The Fibrin Pad product candidate is an excellent example of convergence within Johnson & Johnson, bringing together our medical device and pharmaceutical expertise to bring true innovation to the market," said Dr. Jim Hart, Vice President Medical Affairs, Ethicon, Inc. "The results observed in the clinical trial are very encouraging. This clinical trial is just the first chapter in a stepwise clinical development plan that is ongoing and is intended to evaluate the product candidate in a variety of tissue types and in increasing intensities of bleeding."

The BLA submission includes efficacy and safety data from a randomized, controlled clinical study, in which the Fibrin Pad was used as an adjunct to hemostasis in soft tissue bleeding. The proposed indication is: as an adjunct to hemostasis for
'/>"/>

SOURCE Ethicon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Companys Toolbox
2. First Patient of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices
3. Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM)
4. Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation
5. Ethicon Endo-Surgery Unveils Full Energy Portfolio for First Time at American College of Surgeons Clinical Congress
6. Ethicon Endo-Surgery Introduces Innovation-Enabling Solutions Across the Spectrum of Surgery at ACS
7. Ethicon Completes Acquisition of Acclarent
8. Ethicon Announces Definitive Agreement to Acquire Acclarent
9. Ethicon Endo-Surgery Announces Agreement with Hologic Inc. To Resolve Patent Disputes
10. Ethicon Endo-Surgery SEDASYS(R) System Receives Regulatory Approval in Canada and CE Mark in European Union
11. Ethicon Endo-Surgery Introduces HARMONIC FOCUS(R) Long Curved Shears for Deep Surgical Access
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... PLYMOUTH MEETING, Pa. , Aug. 28, 2014 ... surgical community, patients, and media, both for the ... to patient safety. The quick deployment of surgical ... new technology are prompting facilities to evaluate their ... for the entire surgical team.    ...
(Date:8/28/2014)... 2014 Amgen (NASDAQ: AMGN ) ... (BLA) to the U.S. Food and Drug Administration (FDA) ... cholesterol. Evolocumab is an investigational fully human monoclonal antibody ... protein that reduces the liver,s ability to remove low-density ... 1 ­ The BLA ...
(Date:8/28/2014)... ALISO VIEJO , Kalifornien, 28. ... Inc., hat heute den Start der ... Investigational Device Exemption, Forschungsausnahmegenehmigung) zur Beurteilung ... Systems zur Embolisation von Aneurysmen („WEB") ... University of Tennessee, Department of Neurosurgery/Semmes-Murphey ...
Breaking Medicine Technology:Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3
(Date:8/28/2014)... vaccine to prevent Ebola virus disease will begin next ... Diseases (NIAID), part of the National Institutes of Health. ... of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) ... to generate an immune system response in healthy adults. ... in Bethesda, Maryland. , The study is the first ...
(Date:8/28/2014)... 70 and over who identify themselves as ,old, feel ... perceive they have lower value than younger age groups. ... Kent, titled ,Being old and ill, across different countries: ... used data from the European Social Survey. Respondents, who ... self-rate their health., The researchers found that those living ...
(Date:8/28/2014)... August 28, 2014 Vaccine market - ... great interest among other healthcare industry sectors and sub-circles ... demand in vaccine with respect to evolving and spreading ... due to an improved understanding for a well-balanced life ... States. It has led to new opportunities for manufacturing ...
(Date:8/28/2014)... TX (PRWEB) August 28, 2014 After ... Dr. Paul Vitenas is excited to announce the ... of its kind in any city, Mirror Mirror Beauty ... building. , Situated on the corner of Richmond and ... modern architecture, luxurious amenities, and cutting-edge technology in a ...
(Date:8/28/2014)... Steven Reinberg HealthDay ... Treating pre-cancerous skin spots with a type of light therapy ... the lesions with liquid nitrogen, a new study suggests. ... the scalp and face of people with fair complexions who,ve ... of prior research found that people who underwent the light ...
Breaking Medicine News(10 mins):Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 2Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 3Health News:Mirror Mirror Beauty Boutique to Welcome Its First Patients 2Health News: Light Therapy a Good Option for Pre-Cancerous Skin Lesions, Study Says 2Health News: Light Therapy a Good Option for Pre-Cancerous Skin Lesions, Study Says 3
... fall asleep swiftly if your hands and feet are warmer ... hot baths and// sleeping pills have all been put forward ... nothing beats the dilation of blood vessels in the hands ... ,Dr Kurt Krauchi and his team at the ...
... insomniacs would fare better if they kept the bed for ... A Canadian study found that taking sleeping pills worked in ... a long period. , Insomnia is defined as trouble ... early in the morning without being able to get back ...
... linked high levels of blood fats called triglycerides to ... physicians to pay closer attention to triglyceride levels.// More ... treatments to modify this stroke risk factor could further ... that drugs that lower blood fats can also prevent ...
... breast cancer patients feel better, but it won't help them ... their medical treatment lived an average// of 18 months longer. ... any longer than the 77 who got only medical treatmen. ... and emotional distress -- especially if the levels were high ...
... and other vascular diseases are the leading causes ... in depiction of stenotic, occlusive, aneurismal, inflammatory or ... (DSA) are used to depict vascular lesions with ... material.// It is the gold standard with a ...
... a common liver disease may be caused by the production ... to affect around one in four people in developed countries. ... currently untreatable, and one in ten sufferers go on to ... risk that cancer will develop in the organ.The damage caused ...
Cached Medicine News:Health News:Cure for sleepless nights 2Health News:Magnetic resonance angiography in clinical medicine 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: